Target intelligence / Profile preview

Receptor expression-enhancing protein 6 (REEP6)

Target
REEP6
Molecular classification
Accessory protein, ER resident membrane protein, Membrane-shaping adaptor protein, Other (not a receptor, enzyme, transporter, or transcription factor)
01

Overview

Receptor expression-enhancing protein 6 (REEP6) is a member of the REEP family of endoplasmic reticulum (ER)-resident accessory proteins that shape the membrane architecture of the ER and facilitate the trafficking and localization of specific membrane proteins, including guanylate cyclases essential for retinal phototransduction. REEP6 is localized to the inner segment and outer plexiform layer of rod photoreceptors in the retina. Loss of REEP6 function—via rare recessive mutations—leads to severe retinal degeneration (retinitis pigmentosa) in humans and mice, primarily through disruption of cGMP homeostasis and induction of ER stress, followed by photoreceptor cell death. REEP6 is not itself a classic receptor or enzyme but is essential for the stability, sorting, and homeostasis of other key photoreceptor proteins and organelles. There are no known direct drug interactions, and it is not presently considered a therapeutic target, but its genetic status serves as a biomarker for inherited retinal dystrophy[1][2][3].

Other names
REEP6C19orf32DP1L1FLJ25383Yip2fTB1RP77REEP6.1REEP6.2Polyposis locus protein 1-like 1Deleted in polyposis 1-like 1TB2L1
02

Mechanism of action

Null. No drugs reported.

03

Biological functions

Endoplasmic reticulum (ER) membrane organizationFacilitation of trafficking and stability of phototransduction cascade proteins (especially guanylate cyclases GC1 and GC2)Maintenance of ER and mitochondrial homeostasis in retinal rod photoreceptorsModulation of certain G protein-coupled receptor (GPCR) expression/localization
04

Disease associations

Retinitis pigmentosa (non-syndromic, inherited retinal degeneration)Neurodegenerative disease (general: links to mitochondrial dysfunction in the retina)
05

Safety considerations

Mutations lead to ER stress, organellar dysfunction, and photoreceptor degeneration, but these are pathogenic mechanisms rather than therapy-related safety concernsNo data on therapeutic modulation, so no reported off-target safety concerns
06

Interacting drugs

No approved drugs or small molecules known to directly target REEP6
07

Biomarkers

REEP6 gene mutations (for genetic diagnosis of inherited retinitis pigmentosa)

Beyond the preview

Go deeper on Receptor expression-enhancing protein 6 (REEP6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Receptor expression-enhancing protein 6 (REEP6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call